Bristol-Myers Squibb Licenses Cardiovascular Antisense Target From Isis
This article was originally published in The Pink Sheet Daily
Executive Summary
The latest in a string of deals for Bristol focuses on antisense targets, one of which holds promise for greater LDL cholesterol lowering, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Isis Hits LDL Milestone In Bristol-Myers Squibb Deal
Firm talent-spots PCSK9 compound to the tune of $2 million.
Isis Hits LDL Milestone In Bristol-Myers Squibb Deal
Firm talent-spots PCSK9 compound to the tune of $2 million.
Isis Fourth Quarter Strong, Antisense Rising
Cash from partners keeps company hardy as mipomersen Phase III continues.